Table 1 Demographic and clinical characteristics (descriptive statistics)
Variable | Overall, N = 89 (%) |
|---|---|
Age (years) (mean ± SD) Range | 59.0 ± 12.1 25–81 |
Female | 48 (53.9%) |
BMI (kg/m2) (mean ± SD) | 23.5 ± 6.7 |
Race | |
- White | 50 (56.1%) |
- Black | 6 (6.7%) |
- Brown | 32 (35.9%) |
Schooling | |
- Complete high school | 19 (35.8%) |
- Incomplete high school | 2 (3.8%) |
- Elementary school | 24 (45.3%) |
- Graduation | 3 (5.7%) |
Comorbidity | 73 (82%) |
- Smoking | 45 (50.6%) |
- Alcoholism | 19 (21.4%) |
- Diabetes mellitus | 22 (24.7%) |
- Hypertension | 42 (47.2%) |
- Heart | 4 (4.5%) |
- Pulmonary | 9 (10.1%) |
- Renal | 8 (8.9%) |
- Liver | 3 (3.4%) |
- Autoimmune | 10 (11.2%) |
- Degenerative orthopedic | 4 (4.5%) |
ECOG | |
- 2 | 44 (49.4%) |
- 3 | 42 (47.2%) |
- 4 | 3 (3.4%) |
Cancer | |
- Lung | 23 (25.8%) |
- Breast | 15 (16.9%) |
- Colon | 9 (10.1%) |
- Ovary | 8 (9.0%) |
- Stomach | 5 (5.6%) |
- Prostate | 4 (4.5%) |
Stage T | |
- 1 | 2 (2.3%) |
- 2 | 9 (10.1%) |
- 3 | 11 (12.4%) |
- 4 | 38 (42.7%) |
- Tx | 29 (32.6%) |
Stage N | |
- 0 | 4 (4.5%) |
- 1 | 19 (21.4%) |
- 2 | 10 (11.2%) |
- 3 | 8 (9.0%) |
- Nx | 48 (53.9%) |
Distance metastasis (M1) | 86 (96.6%) |
Number of metastasis Sites | |
- 1 | 29 (32.6%) |
- 2 | 31 (34.8%) |
- 3 | 17 (19.1%) |
- 4 or more | 9 (10.1%) |
Metastasis sites | |
- Lung | 40 (44.9%) |
- Liver | 36 (40.4%) |
- Lymph node | 28 (31.5%) |
- Bone | 23 (25.8%) |
- Peritoneum | 20 (22.47%) |
- Pleura | 15 (16.85%) |
- Central nervous system | 9 (10.11%) |
- Skin | 3 (3.37%) |
- Adrenal gland | 3 (3.37%) |
- Bone marrow | 3 (3.37%) |
Clinal stage | |
- 2 | 1 (1.1%) |
- 3 | 2 (2.2%) |
- 4 | 86 (96.6%) |
Previous chemotherapy lines | |
- 0 | 70 (78.7%) |
- 1 | 11 (12.4%) |
- 2 or more | 8 (8.9%) |
Oncological emergency | 38 (42.7%) |
- Hepatic visceral crisis | 9 (23.7%) |
- Intestinal subocclusion | 8 (21.1%) |
- Superior vena cava syndrome | 7 (18.4%) |
- Spinal cord compression syndrome | 7 (18.4%) |
- Pulmonary lymphangitis | 6 (15.8%) |
- Hypercalcemia | 1 (2.6%) |
Purpose of systemic therapy | |
- Neoadjuvant or adjuvant | 2 (2.2%) |
- Palliative | 87 (97.8%) |
Type of systemic oncological treatment | |
- Chemotherapy | 83 (93.3%) |
- Hormone therapy | 6 (6.7%) |
Reduced chemotherapy dose | 18 (20.2%) |
Other inpatient treatments | |
- Radiotherapy | 9 (10.2%) |
- Surgery | 4 (4.6%) |
Assessment by palliative care team | 30 (33.7%) |
Death (until last assessment) | 75 (84.3%) |
Death within 30 days after chemotherapy | 52 (58.4%) |
Post-chemotherapy survival (days) (mean ± SD) | 74.6 ± 148.1 |
- Spread | 1–863 |
Immediate cause of death | |
Cancer | 53 (73.6%) |
Septic shock | 6 (8.3%) |
Febrile neutropenia | 5 (6.9%) |
Tumor lysis syndrome | 4 (5.6%) |
Respiratory failure | 1 (1.4%) |
Hypovolemic shock | 3 (4.2%) |
ICU admission | 18 (20.2%) |
Performing orotracheal intubation / mechanical ventilation | 16 (18.0%) |
Blood transfusion | 13 (14.6%) |
Central venous catheter insertion | 29 (32.6%) |